Richard (Rick) Barry has served as a Director since June 2021 and was appointed Chief Executive Officer in September 2024. Mr. Barry served as Executive Chairman of the Board beginning July 2024 until his appointment as Chief Executive Officer. Since June 2015, Mr. Barry has also served as Director of Sarepta Therapeutics, Inc., (Nasdaq: SRPT). Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC, and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. Mr. Barry holds a Bachelor of Arts from Pennsylvania State University.

Joe Hulihan joined Filana in August 2025. He has extensive experience in clinical development of treatments for epilepsy and other neurologic and psychiatric disorders. From 2019 to 2025, he was Chief Medical Officer at Marinus Pharmaceuticals, leading development programs in rare pediatric epilepsies and for treatment of status epilepticus. Dr. Hulihan has also served as an advisor or consultant to companies working in Huntington’s Disease, Parkinson’s disease and head trauma in addition to those advancing treatments for seizure disorders. Previously, he worked at Johnson & Johnson in neuroscience drug development and medical affairs for 15 years. He was involved in drug development and post-approval medical support for numerous therapies in the areas of mental health and neurology including epilepsy. Dr. Hulihan graduated from Drexel University School of Medicine in 1986 and received a Master of Science degree in Health Policy from Thomas Jefferson University in 2015.

Chris Cook was appointed Chief Operating and Legal Officer of the Company in April 2025. He joined the Company as Senior Vice President and General Counsel in October 2022. He previously served as the Global Head of Litigation and Government Investigations for Alcon, a publicly traded medical device and pharmaceutical company, as well as the Vice President and division General Counsel for Walmart Central America in San Jose, Costa Rica. Chris also spent seventeen years at Jones Day, where he was a litigation partner in the firm's Washington, DC and Chicago offices. Chris served as an Assistant United States Attorney in Chicago and graduated from Harvard Law School.

Eric Schoen has served as Filana’s Chief Financial Officer since 2018. Prior to joining the Company, Mr. Schoen served as Vice President, Senior Vice President, Finance and Chief Accounting Officer of Aspira Women’s Health Inc. (formerly Vermillion, Inc.), a publicly-held women’s health company, from 2011 to 2017. Mr. Schoen also began his career and spent nine years with PricewaterhouseCoopers in the audit and assurance, transaction services and global capital markets practices.

Angélique Bordey, PhD, joined Filana Therapeutics, Inc. in May 2025. She is the Rothberg Professor and Vice Chair of Research in the Department of Neurosurgery at Yale School of Medicine, where she has led a research lab for 25 years. Dr. Bordey’s laboratory has identified cellular and molecular mechanisms underlying brain malformations and epilepsy in neurological disorders such as tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD). Her work has resulted in four patent applications and more than 130 publications. Dr. Bordey has served on the advisory boards of CURE Epilepsy and the TSC Alliance Preclinical Consortium, and has consulted for several Fortune 500 companies and biotech firms. She is currently a board member of the TSC Alliance. Dr. Bordey earned a BS/MS in chemical engineering from a Grande École in Lyon, France, and an MS/PhD in neuroscience from the University Louis Pasteur in Strasbourg, France.

Jack Moore, PhD, joined the company in April 2025 as the Senior Vice President, Clinical Development. He has over 20 years of leadership experience in the pharmaceutical/biotech industry at Janssen, Novartis, Celgene, Bristol-Meyers Squibb, and Alector. Dr. Moore received his PhD in Neuroscience from the University of North Texas and did a Post-doctoral Fellowship at The University of Texas Southwestern Medical Center.

Mike Zamloot has 35 years of pharmaceutical industry experience with multinational firms and development stage biopharmaceutical companies. He has held his current position with Filana Therapeutics since 2000, and has responsibility for all aspects of Pharmaceutical Development, Quality and Supply Chain Management. Mike holds a BS degree in Chemical Engineering with honors from the New Jersey Institute of Technology and is an inventor on more than 25 patents.

Ben Thornton has over 30 years experience in leading research and development teams in large pharma (Johnson & Johnson) and start up biotechnology companies (GeneMedicine, Apovia) translating basic science to the clinical setting. He has held his current position with Filana Therapeutics since 2005. Ben holds a PhD in Molecular Biology from the University of Texas M.D. Anderson School of Biomedical Sciences and was a post-doctoral fellow at the Roche Institute of Molecular Biology. He was formerly a Trustee of The Torrey Pines Institute for Molecular Sciences.

Nancy joined the company in November 2025 and is an accomplished regulatory affairs professional with over 30 years of experience in the pharmaceutical and biotechnology industry. She possesses a deep understanding of the complex regulatory landscape governing drug development, clinical trials, manufacturing controls, and product approvals. Nancy is skilled in working directly with the FDA's Center for Drug Evaluation and Research (CDER) and the Office of Orphan Drugs (OOD), having effectively partnered with the Oncology, Neurology, Urology, and Dermatology Divisions within CDER.